HELIXMITH
LIVE

Serial Number

88166343

Owner

ViroMed Co., Ltd.

Attorney

Connie L. Ellerbach

Filing Date

Oct 23, 2018

Add to watchlist:

No watchlists yet
View on USPTO

HELIXMITH Trademark

Serial Number: 88166343 • Registration: 5906698

HELIXMITH is a trademark filed by ViroMed Co., Ltd. on October 23, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

ViroMed Co., Ltd. (5 trademarks)

5th Fl.Bldg. 203, Seoul Nat'l University
Seoul 08826 , KR

Entity Type: 03

Helixmitth Co., Ltd

1 Gwanak-ro 5th Fl. Bldg. 203
Seoul 08826 , KR

Entity Type: 03

Trademark Details

Filing Date

October 23, 2018

Registration Date

November 12, 2019

Published for Opposition

May 28, 2019

Goods & Services

reagents for use in veterinary genetic testing for medical use; chemical preparations for pharmaceutical purposes, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; chemical preparations for use in DNA analysis for medical use; drugs for medical purposes, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; reagents for use in medical genetic testing for medical use; pharmaceutical drugs, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; medicines for human purposes, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; pharmaceutical preparations for diagnosis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; ethical medicinal preparations, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; therapeutic drugs and agents, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; biological preparations, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; crude medicines, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; biological preparations for medical use in medical and clinical gene therapy and cell therapy; pharmaceutical preparations, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; biological preparations for medical use, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer

Retail store services featuring reagents for use in veterinary genetic testing; retail store services featuring chemical preparations for pharmaceutical purposes; retail store services featuring chemical preparations for use in DNA analysis for medical use; retail store services featuring drugs for medical purposes; retail store services featuring reagents for use in medical genetic testing; retail store services featuring pharmaceutical preparations for diagnosis; retail store services featuring pharmaceutical preparations for the treatment of immune system related diseases and disorders; retail store services featuring ethical medicinal preparations; retail store services featuring therapeutic drugs and agents, retail store services featuring biological preparations for medical use

Research and development of vaccines and medicines; providing information relating to scientific analysis of the genetic information via online networks; scientific research in the fields of biomedicine; biological information analysis, namely, genetic testing for medical research purposes; biological information analysis, namely, genetic testing for scientific research purposes; research and testing services in the fields of bacteriology and virology; drug discovery services; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy relating to the pharmaceutical research and development; pharmaceutical research and development; pharmaceutical research services; laboratory research in the field of gene expression; gene analysis for research; consultancy in analysis of biology sequence processing for medical research purposes; consultancy in analysis of genomics for medical research purposes; scientific research in the fields of medicine/health and pharmacology; analysis of human serum for medical research; analysis of human tissues for medical research; blood analysis services

Filing History

TEAS SECTION 8 & 15 RECEIVED
Apr 24, 2026 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Nov 12, 2024 REM1
CORRECTION UNDER SECTION 7 - PROCESSED
Aug 25, 2020 COC.
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Aug 10, 2020 EROP
POST REGISTRATION ACTION MAILED - SEC. 7
Feb 19, 2020 PRAM
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 18, 2020 APRE
POST REGISTRATION ACTION CORRECTION
Feb 18, 2020 XXXX
OTQR WITHDRAWAL FROM PUBLICATION
Feb 18, 2020 WDRL
CORRECTION UNDER SECTION 7 - PROCESSED
Jan 21, 2020 COC.
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 21, 2020 APRE
TEAS SECTION 7 REQUEST RECEIVED
Dec 3, 2019 ES7R
REGISTERED-PRINCIPAL REGISTER
Nov 12, 2019 R.PR
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Oct 6, 2019 ETOP
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jun 19, 2019 ASCK
EXTENSION OF TIME TO OPPOSE RECEIVED
Jun 11, 2019 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 28, 2019 NPUB
PUBLISHED FOR OPPOSITION
May 28, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 8, 2019 NONP
ELECTRONIC RECORD REVIEW COMPLETE
Apr 22, 2019 FIXD
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
Apr 12, 2019 ERRR
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 3, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Apr 3, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Apr 3, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Apr 3, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Apr 3, 2019 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 30, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 29, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 29, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 22, 2019 GNRN
NON-FINAL ACTION E-MAILED
Mar 22, 2019 GNRT
NON-FINAL ACTION WRITTEN
Mar 22, 2019 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 13, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 13, 2019 CRFA
ASSIGNED TO LIE
Mar 8, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 5, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 5, 2019 GNRN
NON-FINAL ACTION E-MAILED
Jan 5, 2019 GNRT
NON-FINAL ACTION WRITTEN
Jan 5, 2019 CNRT
ASSIGNED TO EXAMINER
Jan 3, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 5, 2018 NWOS
NEW APPLICATION ENTERED
Oct 26, 2018 NWAP